Jpmorgan Chase & CO Applied Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 53,907 shares of APLT stock, worth $24,258. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,907
Previous 51,550
4.57%
Holding current value
$24,258
Previous $43,000
39.53%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding APLT
# of Institutions
95Shares Held
103MCall Options Held
176KPut Options Held
165K-
Vestal Point Capital, LP New York, NY11.5MShares$5.18 Million0.4% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA11.3MShares$5.08 Million6.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$4.67 Million0.0% of portfolio
-
Knoll Capital Management, LLC Miami, FL7.8MShares$3.51 Million2.55% of portfolio
-
Black Rock Inc. New York, NY6.57MShares$2.96 Million0.0% of portfolio
About Applied Therapeutics Inc.
- Ticker APLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,020,700
- Market Cap $21.6M
- Description
- Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...